false
0001537561
0001537561
2024-10-29
2024-10-29
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): October 29, 2024
ARCH
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
| Nevada |
|
000-54986 |
|
46-0524102 |
| (State
or other jurisdiction |
|
(Commission |
|
(I.R.S.
Employer |
| of
incorporation) |
|
File
Number) |
|
Identification
No.) |
| 235
Walnut Street, Suite 6 |
|
|
| Framingham,
Massachusetts |
|
01702 |
| (Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (617) 431-2313
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| N|A |
|
N|A |
|
N|A |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
1.01 Entry into a Material Definitive Agreement.
Amendments
to 2022 Notes and 2024 Notes
Effective
October 29, 2024, Arch Therapeutics, Inc. (the “Company”) entered into an amendment (“Amendment No. 20 to
the First 2022 Notes”) with the holders of the Company’s outstanding Senior Secured Convertible Promissory Notes, as
separately amended on February 14, 2023, March 10, 2023, March 15, 2023, April 15, 2023, May 15, 2023, June 15, 2023, July 1, 2023, July
7, 2023, July 31, 2023, August 30, 2023, September 30, 2023, October 31, 2023, November 15, 2023, January 5, 2024, March 15, 2024, April
30, 2024, June 30, 2024, August 15, 2024 and September 15, 2024 (as amended, the “First 2022 Notes”), issued in connection
with a private placement financing the Company completed on July 6, 2022.
Effective
October 29, 2024, the Company also entered into an amendment (“Amendment No. 20 to the Second 2022 Notes”) with the
holders of the Company’s outstanding Unsecured Convertible Promissory Notes, as separately amended on February 14, 2023, March
10, 2023, March 15, 2023, April 15, 2023, May 15, 2023, June 15, 2023, July 1, 2023, July 7, 2023, July 31, 2023, August 30, 2023, September
30, 2023, October 31, 2023, November 15, 2023, January 5, 2024, March 15, 2024, April 30, 2024, June 30, 2024, August 15, 2024 and September
15, 2024 (as amended, the “Second 2022 Notes”), issued in connection with a private placement financing the Company
completed on January 18, 2023.
Effective
October 29, 2024, the Company also entered into an amendment (“Amendment No. 15 to the Third 2022 Notes”) with the
holders of the Company’s outstanding Unsecured Convertible Promissory Notes, as separately amended on June 15, 2023, July 1, 2023,
July 7, 2023, July 31, 2023, August 30, 2023, September 30, 2023, October 31, 2023, November 15, 2023, January 5, 2024, March 15, 2024,
April 30, 2024, June 30, 2024, August 15, 2024 and September 15, 2024 (as amended, the “Third 2022 Notes”), issued
in connection with a private placement financing the Company completed on May 15, 2023.
Effective
October 29, 2024, the Company also entered into an amendment (“Amendment No. 6 to the Fourth 2022 Notes”) with the
holders of the Company’s outstanding Unsecured Convertible Promissory Notes, as separately amended on March 15, 2024, April 30,
2024, June 30, 2024, August 15, 2024 and September 15, 2024 issued in connection with a private placement financing the Company completed
on March 12, 2024 (as amended, the “Fourth 2022 Notes”).
Effective
October 29, 2024, the Company also entered into an amendment (“Amendment No. 4 to the First 2024 Notes” and, together
with Amendment No. 20 to the First 2022 Notes, Amendment No. 20 to the Second 2022 Notes, Amendment No. 15 to the Third 2022 Notes and
Amendment No. 6 to the Fourth 2022 Notes, the “Amendments to the Notes”) with the holders of the Company’s outstanding
Senior Secured Convertible Promissory Notes, as separately amended on June 30, 2024, August 15, 2024 and September 15, 2024 issued in
connection with a private placement financing the Company completed on May 15, 2024 (as amended, the “First 2024 Notes”
and, together with the First 2022 Notes, Second 2022 Notes, Third 2022 Notes and Fourth 2022 Notes, the “Notes”).
Under
the Amendments to the Notes, the Notes were amended to extend the date of the completion of an “Uplist” (as defined therein)
and to extend the respective maturity date of each of the Notes from September 30, 2024 to November 30, 2024. In addition to the foregoing,
Amendment No. 4 to the First 2024 Notes also increased the outstanding principal amount of the Additional Notes issued in connection
with the Fourth Closing, Fifth Closing, Sixth Closing, Seventh Closing and Eighth Closing in connection with the SPA dated May 15, 2024,
as amended on September 15, 2024, by a factor of 1.03.
The
preceding descriptions of Amendment No. 20 to the First 2022 Notes, Amendment No. 20 to the Second 2022 Notes, Amendment No. 15 to the
Third 2022 Notes, Amendment No. 6 to the Fourth 2022 Notes, and Amendment No. 4 to the First 2024 Notes are qualified in their entirety
by reference to the copies of the Forms of Amendment No. 20 to the First 2022 Notes, Amendment No. 20 to the Second 2022 Notes, Amendment
No. 15 to the Third 2022 Notes, Amendment No. 6 to the Fourth 2022 Notes, and Amendment No. 4 to the First 2024 Notes filed herewith
as Exhibit 10.1, Exhibit 10.2, Exhibit 10.3, Exhibit 10.4, and Exhibit 10.5 to this Current Report on Form 8-K, respectively, which are
incorporated herein by reference.
Item
9.01 Financial Statements and Exhibits.
(d)
The following exhibits are being filed herewith:
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
ARCH
THERAPEUTICS, INC. |
| |
|
| Dated:
November 4, 2024 |
By: |
/s/
Terrence W. Norchi, M.D. |
| |
Name:
|
Terrence
W. Norchi, M.D. |
| |
Title:
|
President,
Chief Executive Officer |
Exhibit 10.1
AMENDMENT
NO. 20
TO
SENIOR
SECURED CONVERTIBLE PROMISSORY NOTE
This
Amendment No. 20 (this “Amendment”) to those certain Senior Secured Convertible Promissory Notes, as amended on February
14, 2023, and as subsequently amended on March 10, 2023, March 15, 2023, April 15, 2023, May 15, 2023, June 15, 2023, July 1, 2023, July
7, 2023, July 31, 2023, August 30, 2023, September 30, 2023, October 31, 2023, November 15, 2023, January 5, 2024, March 15, 2024, April
30, 2024, June 30, 2024, August 15, 2024 and September 15, 2024 (as amended, the “First Notes”), issued by Arch Therapeutics,
Inc., a Nevada corporation (the “Company”), to each Holder pursuant to that certain Securities Purchase Agreement,
dated July 6, 2022, by and among the Company and the signatories thereto (the “Holders”), as amended on January 18,
2023, May 15, 2023 and March 12, 2024 (as amended, the “Securities Purchase Agreement”) is made and entered into effective
October 29, 2024 by and among the Company and the Consenting Stockholders (as defined below). Capitalized terms used herein but not otherwise
defined shall have the meanings ascribed to them in the Securities Purchase Agreement.
W
I T N E S S E T H:
WHEREAS,
pursuant to Section 4.3 of the First Notes and Section 7(e) of the Securities Purchase Agreement, the First Notes may be amended in a
written instrument signed by the Company, the Lead Investor, and Holders which purchased at least 50% plus $1.00 of the Notes based on
the initial Principal Amounts thereunder (the Lead Investor and such Holders, collectively the “Consenting Stockholders”);
and
WHEREAS,
the undersigned Holders constitute the Consenting Stockholders.
NOW,
THEREFORE, in exchange for good and valuable consideration including, without limitation, the mutual covenants contained herein,
the sufficiency of which is hereby acknowledged, and intending to be legally bound hereby, the parties hereby agree as follows:
1. Amendments to the First Notes.
1.1
The First Notes are hereby amended by deleting the words “September 30, 2024” in the first paragraph of the First Notes
and replacing such words with the following words in substitution therefor:
“November
30, 2024”
1.2
The First Notes are hereby amended by deleting the words “by September 30, 2024” in Section 3.23 of the First Notes and
replacing such words with the following sentence in substitution therefor:
“by
November 30, 2024”
2. Miscellaneous.
2.1
The “First Note Amendment Termination Date” is hereby extended to November 30, 2024.
2.2
Except as expressly amended by this Amendment, the terms and provisions of the First Notes shall continue in full force and effect.
No reference to this Amendment need be made in any instrument or document making reference to the First Notes; any reference to the First
Notes in any such instrument or document shall be deemed a reference to the First Notes as amended hereby. The First Notes as amended
hereby shall be binding upon the parties thereto and their respective assigns and successors.
2.3
This Amendment shall be governed by and construed in accordance with the laws of the State of Nevada as such laws are applied to
agreements between parties in Nevada.
2.4
This Amendment may be executed in separate counterparts, each such counterpart being deemed to be an original instrument, and all
such counterparts shall together constitute the same agreement.
[Signature
Pages Follow]
IN
WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first written above.
| |
ARCH THERAPEUTICS, INC. |
| |
|
|
| |
By: |
|
| |
Name: |
Michael S. Abrams |
| |
Title: |
Chief Financial Officer |
Signature
Page to Amendment No. 20 to the First Notes
IN
WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first written above.
Signature
Page to Amendment No. 20 to the First Notes
Exhibit 10.2
AMENDMENT
NO. 20
TO
UNSECURED
CONVERTIBLE PROMISSORY NOTE
This
Amendment No. 20 (this “Amendment”) to those certain Unsecured Convertible Promissory Notes, as amended on February
14, 2023, and as subsequently amended on March 10, 2023, March 15, 2023, April 15, 2023, May 15, 2023, June 15, 2023, July 1, 2023, July
7, 2023, July 31, 2023, August 30, 2023, September 30, 2023, October 31, 2023, November 15, 2023, January 5, 2024, March 15, 2024, April
30, 2024, June 30, 2024, August 15, 2024 and September 15, 2024 (as amended, the “Second Notes”), issued by Arch Therapeutics,
Inc., a Nevada corporation (the “Company”), to certain Holders pursuant to that certain Securities Purchase Agreement,
dated July 6, 2022, by and among the Company and the signatories thereto (the “Holders”), as amended on January 18,
2023, May 15, 2023 and March 12, 2024 (as amended, the “Securities Purchase Agreement”) is made and entered into effective
October 29, 2024 by and among the Company and the Consenting Stockholders (as defined below). Capitalized terms used herein but not otherwise
defined shall have the meanings ascribed to them in the Securities Purchase Agreement.
W
I T N E S S E T H:
WHEREAS,
pursuant to Section 4.3 of the Second Notes and Section 7(e) of the Securities Purchase Agreement, the Second Notes may be amended in
a written instrument signed by the Company, the Lead Investor, and Holders which purchased at least 50% plus $1.00 of the Notes based
on the initial Principal Amounts thereunder (the Lead Investor and such Holders, collectively the “Consenting Stockholders”);
and
WHEREAS,
the undersigned Holders constitute the Consenting Stockholders.
NOW,
THEREFORE, in exchange for good and valuable consideration including, without limitation, the mutual covenants contained herein,
the sufficiency of which is hereby acknowledged, and intending to be legally bound hereby, the parties hereby agree as follows:
1.
Amendments to the Second Notes.
1.1
The Second Notes are hereby amended by deleting the words “September 30, 2024” in the first paragraph of the Second Notes
and replacing such words with the following words in substitution therefor:
“November
30, 2024”
1.2
The Second Notes are hereby amended by deleting the words “by September 30, 2024” in Section 3.23 of the Second Notes
and replacing such words with the following sentence in substitution therefor:
“by
November 30, 2024”
2.
Miscellaneous.
2.1
The “Second Note Amendment Termination Date” is hereby extended to November 30, 2024.
2.2
Except as expressly amended by this Amendment, the terms and provisions of the Second Notes shall continue in full force and effect.
No reference to this Amendment need be made in any instrument or document making reference to the Second Notes; any reference to the
Second Notes in any such instrument or document shall be deemed a reference to the Second Notes as amended hereby. The Second Notes as
amended hereby shall be binding upon the parties thereto and their respective assigns and successors.
2.3
This Amendment shall be governed by and construed in accordance with the laws of the State of Nevada as such laws are applied to
agreements between parties in Nevada.
2.4
This Amendment may be executed in separate counterparts, each such counterpart being deemed to be an original instrument, and all
such counterparts shall together constitute the same agreement.
[Signature
Pages Follow]
IN
WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first written above.
| |
ARCH THERAPEUTICS, INC. |
| |
|
|
| |
By: |
|
| |
Name: |
Michael S. Abrams |
| |
Title: |
Chief Financial Officer |
Signature
Page to Amendment No. 20 to the Second Notes
IN
WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first written above.
Signature
Page to Amendment No. 20 to the Second Notes
Exhibit 10.3
AMENDMENT
NO. 15
TO
UNSECURED
CONVERTIBLE PROMISSORY NOTE
This
Amendment No. 15 (this “Amendment”) to those certain Unsecured Convertible Promissory Notes, as amended on June 15,
2023, and as subsequently amended on July 1, 2023, July 7, 2023, July 31, 2023, August 30, 2023, September 30, 2023, October 31, 2023,
November 15, 2023, January 5, 2024, March 15, 2024, April 30, 2024, June 30, 2024, August 15, 2024 and September 15, 2024(as amended,
the “Third Notes”), issued by Arch Therapeutics, Inc., a Nevada corporation (the “Company”), to
each Holder pursuant to that certain Securities Purchase Agreement, dated July 6, 2022, by and among the Company and the signatories
thereto (the “Holders”), as amended on January 18, 2023, May 15, 2023 and March 12, 2024 (as amended, the “Securities
Purchase Agreement”) is made and entered into effective October 29, 2024 by and among the Company and the Consenting Stockholders
(as defined below). Capitalized terms used herein but not otherwise defined shall have the meanings ascribed to them in the Securities
Purchase Agreement.
W
I T N E S S E T H:
WHEREAS,
pursuant to Section 4.3 of the Third Notes and Section 7(e) of the Securities Purchase Agreement, the Third Notes may be amended in a
written instrument signed by the Company, the Lead Investor, and Holders which purchased at least 50% plus $1.00 of the Notes based on
the initial Principal Amounts thereunder (the Lead Investor and such Holders, collectively the “Consenting Stockholders”);
and
WHEREAS,
the undersigned Holders constitute the Consenting Stockholders.
NOW,
THEREFORE, in exchange for good and valuable consideration including, without limitation, the mutual covenants contained herein,
the sufficiency of which is hereby acknowledged, and intending to be legally bound hereby, the parties hereby agree as follows:
1.
Amendments to the Third Notes.
1.1
The Third Notes are hereby amended by deleting the words “September 30, 2024” in the first paragraph of the Third Notes
and replacing such words with the following words in substitution therefor:
“November
30, 2024”
1.2
The Third Notes are hereby amended by deleting the words “by September 30, 2024” in Section 3.23 of the Third Notes and
replacing such words with the following words in substitution therefor:
“by
November 30, 2024”
2.
Miscellaneous.
2.1
The “Third Note Amendment Termination Date” is hereby extended to November 30, 2024.
2.2
Except as expressly amended by this Amendment, the terms and provisions of the Third Notes shall continue in full force and effect.
No reference to this Amendment need be made in any instrument or document making reference to the Third Notes; any reference to the Third
Notes in any such instrument or document shall be deemed a reference to the Third Notes as amended hereby. The Third Notes as amended
hereby shall be binding upon the parties thereto and their respective assigns and successors.
2.3
This Amendment shall be governed by and construed in accordance with the laws of the State of Nevada as such laws are applied to
agreements between parties in Nevada.
2.4
This Amendment may be executed in separate counterparts, each such counterpart being deemed to be an original instrument, and all
such counterparts shall together constitute the same agreement.
[Signature
Pages Follow]
IN
WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first written above.
| |
ARCH THERAPEUTICS, INC. |
| |
|
|
| |
By: |
|
| |
Name: |
Michael S. Abrams |
| |
Title: |
Chief Financial Officer |
Signature
Page to Amendment No. 15 to the Third Notes
IN
WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first written above.
Signature
Page to Amendment No. 15 to the Third Notes
Exhibit
10.4
AMENDMENT
NO. 6
TO
UNSECURED
CONVERTIBLE PROMISSORY NOTE
This
Amendment No. 6 (this “Amendment”) to those certain Unsecured Convertible Promissory Notes, as amended on March 15,
2024, and as subsequently amended on April 30, 2024, June 30, 2024, August 15, 2024 and September 15, 2024 (as amended, the “Fourth
Notes”), issued by Arch Therapeutics, Inc., a Nevada corporation (the “Company”), to each Holder pursuant
to that certain Securities Purchase Agreement, dated July 6, 2022, by and among the Company and the signatories thereto (the “Holders”),
as amended on January 18, 2023, May 15, 2023 and March 12, 2024 (as amended, the “Securities Purchase Agreement”)
is made and entered into effective October 29, 2024 by and among the Company and the Consenting Stockholders (as defined below). Capitalized
terms used herein but not otherwise defined shall have the meanings ascribed to them in the Securities Purchase Agreement.
W
I T N E S S E T H:
WHEREAS,
pursuant to Section 4.3 of the Fourth Notes and Section 7(e) of the Securities Purchase Agreement, the Fourth Notes may be amended in
a written instrument signed by the Company, the Lead Investor, and Holders which purchased at least 50% plus $1.00 of the Notes based
on the initial Principal Amounts thereunder (the Lead Investor and such Holders, collectively the “Consenting Stockholders”);
and
WHEREAS,
the undersigned Holders constitute the Consenting Stockholders.
NOW,
THEREFORE, in exchange for good and valuable consideration including, without limitation, the mutual covenants contained herein,
the sufficiency of which is hereby acknowledged, and intending to be legally bound hereby, the parties hereby agree as follows:
1.
Amendments to the Fourth Notes.
1.1
The Fourth Notes are hereby amended by deleting the words “September 30, 2024” in the first paragraph of the Fourth Notes
and replacing such words with the following words in substitution therefor:
“November
30, 2024”
1.2
The Fourth Notes are hereby amended by deleting the words “by September 30, 2024” in Section 3.23 of the Fourth Notes
and replacing such words with the following sentence in substitution therefor:
“by
November 30, 2024”
2.
Miscellaneous.
2.1
The “Fourth Note Amendment Termination Date” is hereby extended to November 30, 2024.
2.2
Except as expressly amended by this Amendment, the terms and provisions of the Fourth Notes shall continue in full force and effect.
No reference to this Amendment need be made in any instrument or document making reference to the Fourth Notes; any reference to the
Fourth Notes in any such instrument or document shall be deemed a reference to the Fourth Notes as amended hereby. The Fourth Notes as
amended hereby shall be binding upon the parties thereto and their respective assigns and successors.
2.3
This Amendment shall be governed by and construed in accordance with the laws of the State of Nevada as such laws are applied to
agreements between parties in Nevada.
2.4
This Amendment may be executed in separate counterparts, each such counterpart being deemed to be an original instrument, and all
such counterparts shall together constitute the same agreement.
[Signature
Pages Follow]
IN
WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first written above.
| |
ARCH
THERAPEUTICS, INC. |
| |
|
|
| |
By: |
|
| |
Name: |
Michael S. Abrams |
| |
Title: |
Chief Financial Officer |
Signature
Page to Amendment No. 6 to the Fourth Notes
IN
WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first written above.
Signature
Page to Amendment No. 6 to the Fourth Notes
Exhibit
10.5
AMENDMENT
NO. 4
TO
SENIOR
SECURED CONVERTIBLE PROMISSORY NOTE
This
Amendment No. 4 (this “Amendment”) to those certain Senior Secured Convertible Promissory Notes issued by Arch Therapeutics,
Inc., a Nevada corporation (the “Company”), to each Holder pursuant to that certain Securities Purchase Agreement,
dated May 15, 2024, and as subsequently amended on June 30, 2024, August 15, 2024 and September 15, 2024 (as amended, the “First
Notes”, and, together with the “Additional Notes”, the “Notes”), by and among the Company and the signatories
thereto (the “Holders”) (the “Securities Purchase Agreement”) is made and entered into effective
October 29, 2024 by and among the Company and the Consenting Stockholders (as defined below). Capitalized terms used herein but not otherwise
defined shall have the meanings ascribed to them in the Securities Purchase Agreement.
W
I T N E S S E T H:
WHEREAS,
pursuant to Section 4.3 of the First Notes and Section 7(e) of the Securities Purchase Agreement, the First Notes may be amended in a
written instrument signed by the Company and Holders which purchased at least 50% plus $1.00 of the Notes based on the initial Principal
Amounts thereunder (such Holders, the “Consenting Stockholders”); and
WHEREAS,
the undersigned Holders constitute the Consenting Stockholders.
NOW,
THEREFORE, in exchange for good and valuable consideration including, without limitation, the mutual covenants contained herein,
the sufficiency of which is hereby acknowledged, and intending to be legally bound hereby, the parties hereby agree as follows:
1.
Amendments to the First Notes.
1.1
The First Notes are hereby amended by deleting the words “September 30, 2024” in the first paragraph of the First Notes
and replacing such words with the following words in substitution therefor:
“November
30, 2024”
1.2
The First Notes are hereby amended by deleting the words “by September 30, 2024” in Section 3.23 of the First Notes and
replacing such words with the following sentence in substitution therefor:
“by
November 30, 2024”
2.
Miscellaneous.
2.1
The “First Note Amendment Termination Date” is November 30, 2024.
2.2
The outstanding principal amount of the Additional Notes issued in connection with the Fourth Closing, Fifth Closing, Sixth Closing
and Seventh Closing shall be further increased by an additional factor of 1.03, and the outstanding principal amount of the Additional
Notes issued in connection with the Eighth Closing shall be increased by a factor of 1.03.
2.3
Except as expressly amended by this Amendment, the terms and provisions of the First Notes shall continue in full force and effect.
No reference to this Amendment need be made in any instrument or document making reference to the First Notes; any reference to the First
Notes in any such instrument or document shall be deemed a reference to the First Notes as amended hereby. The First Notes as amended
hereby shall be binding upon the parties thereto and their respective assigns and successors.
2.4
This Amendment shall be governed by and construed in accordance with the laws of the State of Nevada as such laws are applied to
agreements between parties in Nevada.
2.5
This Amendment may be executed in separate counterparts, each such counterpart being deemed to be an original instrument, and all
such counterparts shall together constitute the same agreement.
[Signature
Pages Follow]
IN
WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first written above.
| |
ARCH
THERAPEUTICS, INC. |
| |
|
|
| |
By: |
|
| |
Name: |
Michael S. Abrams |
| |
Title: |
Chief Financial Officer |
Signature
Page to Amendment No. 4 to the Notes
IN
WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first written above.
Signature
Page to Amendment No. 4 to the Notes
v3.24.3
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 2 such as Street or Suite number
| Name: |
dei_EntityAddressAddressLine2 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
Arch Therapeutics (QB) (USOTC:ARTH)
過去 株価チャート
から 11 2024 まで 12 2024
Arch Therapeutics (QB) (USOTC:ARTH)
過去 株価チャート
から 12 2023 まで 12 2024
